45a758dc-af09-48d3-8cd2-15232593f385
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.610
- E2F_TARGETS+0.590
- G2M_CHECKPOINT+0.450
- DNA_REPAIR+0.440
- OXIDATIVE_PHOSPHORYLATION+0.440
- MYC_TARGETS_V2+0.430
- UNFOLDED_PROTEIN_RESPONSE+0.400
- MTORC1_SIGNALING+0.380
- PROTEIN_SECRETION+0.260
- SPERMATOGENESIS+0.210
Top 10 suppressed
- NOTCH_SIGNALING-0.440
- MYOGENESIS-0.400
- HEDGEHOG_SIGNALING-0.390
- APICAL_JUNCTION-0.360
- ESTROGEN_RESPONSE_EARLY-0.360
- APICAL_SURFACE-0.350
- COAGULATION-0.350
- INTERFERON_GAMMA_RESPONSE-0.320
- IL6_JAK_STAT3_SIGNALING-0.310
- INFLAMMATORY_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_YBJBSRHV | Embryonal tumors | — | 0.940 |
| 2 | TCGA-C8-A1HN-01A-11R-A137-07 | — | B | 0.923 |
| 3 | SRR12475130 | — | — | 0.922 |
| 4 | 4e2a5058-c190-49de-97f4-0ba7be7ebfe8 | — | — | 0.915 |
| 5 | TCGA-91-8499-01A-11R-2403-07 | — | cohortMD1 | 0.905 |
| 6 | debb199a-24be-4e87-84ea-2df67673457a | — | — | 0.903 |
| 7 | 1c3eaf9a-ffda-4c6d-bffb-2610a37ab837 | — | — | 0.900 |
| 8 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.900 |
| 9 | MBCproject_0227_T2_RNA | — | B | 0.898 |
| 10 | TCGA-AN-A0AK-01A-21R-A00Z-07 | — | C | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.610 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.440 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |